Examkin

Question

Difficulty: EasyNeoplastic Processes

A 72-year-old man with newly diagnosed metastatic prostate cancer is initiated on continuous leuprolide therapy. Seven days later, he contacts the clinic to report new, acutely worsened bone pain in his lower back and ribs. His neurologic examination is unremarkable, and he has normal bowel and bladder function. Which of the following best describes the pathophysiologic mechanism underlying this patient's acute exacerbation of symptoms?

  1. Initial surge in testosterone production secondary to transient pituitary stimulationAnswer
  2. B
    Accelerated proliferation of neoplastic cells due to rapid disease progression
  3. C
    Direct osteoclast activation and bone resorption mediated by the prescribed medication
  4. D
    Ectopic secretion of parathyroid hormone-related peptide causing bone demineralization
  5. E
    Systemic hypercoagulability leading to microvascular thrombosis in the vertebral bodies

Answer

Initial surge in testosterone production secondary to transient pituitary stimulation
Leuprolide is a gonadotropin-releasing hormone (GnRH) analog used in the management of advanced prostate cancer. When administered continuously, it ultimately causes downregulation and desensitization of GnRH receptors on the anterior pituitary, leading to a profound decrease in luteinizing hormone (LH) and testosterone levels (medical castration). However, during the first 1 to 2 weeks of therapy, the agonist directly stimulates the pituitary to release a bolus of LH, resulting in a transient surge in testosterone production from the testes. In a patient with hormone-sensitive metastatic prostate cancer, this testosterone surge transiently stimulates tumor growth, causing a clinical 'flare' phenomenon. This classic flare frequently presents as acutely worsened bone pain in areas of metastasis and requires co-administration of an androgen receptor antagonist (e.g., flutamide) during the initial weeks of therapy to block the effects of the testosterone surge.

Step-by-Step Solution

1
Identify the mechanism of action of the prescribed medication.
Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist.
Understanding the drug class is required to anticipate its physiological effects on the endocrine axis.
2
Determine the initial endocrine response to continuous GnRH agonist therapy.
During the first 1 to 2 weeks, there is a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which increases testosterone production.
Before the pituitary receptors downregulate to suppress the axis, they are initially stimulated by the agonist.
3
Correlate the endocrine response with the patient's acute clinical presentation.
The temporary rise in testosterone stimulates the hormone-sensitive metastatic prostate cancer cells in the bone, causing a 'tumor flare' that manifests as acutely worsened pain.
This establishes the direct pathophysiological link between the timing of the intervention and the onset of new symptoms.

Key Concept

GnRH agonists initially stimulate the pituitary gland, causing a transient surge in testosterone that can lead to a symptomatic tumor flare in metastatic prostate cancer.
Rate this question

Topics

Neoplastic Processes

More questions from this topic